Most disability accumulation in relapsing multiple sclerosis (MS) is not associated with overt relapses, challenging the current clinical distinction of relapsing and progressive forms of the disease, ...

This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis. NICE has said Biogen's Tysabri can now be used by the NHS ...

Please provide your email address to receive an email when new articles are posted on . No new safety signals or serious adverse events were reported. Of 124 participants who received tolebrutinib 60 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Results from the EVOLVE-MS-1 study show Vumerity was ...

Disease-modifying treatments (DMTs) are the gold standard of multiple sclerosis (MS) therapy. They’ve been extensively researched, leading to an evidence base substantiating their efficacy through ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...